Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Episodic Migraine

Episodic Migraine

Part of Migraine

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Episodic Migraine

18 trials tracked for Episodic Migraine: 16 in phase 3 or 4 and 14 with published results. The most-cited published study has 77 citations.

18Trials tracked
16Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 6 Phase 3 10 Phase 2 1 Other / NA 1
  1. Phase 3 Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. Completed · 77 cited
  2. Phase 3 Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients Completed · 67 cited
  3. Phase 3 A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies Completed · 50 cited
  4. Phase 4 A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Completed · 44 cited
  5. Phase 3 A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine Completed · 37 cited
  6. Phase 3 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine Completed · 36 cited
Show 12 more trials
  1. Phase 4 Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients Completed · 32 cited
  2. Phase 3 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine Completed · 27 cited
  3. Phase 3 DFN-11 Injection in Episodic Migraine With or Without Aura Completed · 25 cited
  4. Phase 4 Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine Completed · 11 cited
  5. Phase 4 Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack Completed · 10 cited
  6. Phase 3 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine Completed · 10 cited
  7. Phase 4 Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention Completed · 2 cited
  8. Phase 3 A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine Completed
  9. Phase 4 The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Completed
  10. Phase 3 Occipital Blocks for Acute Migraine Completed
  11. Phase 2 Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine Completed
  12. N/A Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Episodic Migraine: what the trials found

Several pharmacological interventions demonstrated significant efficacy in reducing monthly migraine days (MMD). AMG334 showed a statistically significant reduction in MMD compared to placebo at week 52 (-2.55 vs -0.55, p<0.001) and achieved a significantly higher percentage of patients reaching a 50% reduction from baseline 2. Atogepant demonstrated consistent reductions in mean monthly migraine days over a 12-week period across multiple trials [7, 14], with significant improvements also noted in the number of acute medication use days 14.

Galcanezumab was associated with a significant reduction in monthly migraine headache days (MHDs) and improved quality-of-life scores 10. In another study, Galcanezumab showed consistent response rates across treatment groups for 50%, 75%, and 100% reductions over a 3-month period 1. Erenumab also demonstrated significant reductions in MMD at month 3 8 and a corresponding decrease in acute migraine-specific medication treatment days 8.

Acute treatments showed varying results: DFN-11 reported higher rates of patients being pain-free at 2 hours compared to 1 hour 13, while Maxalt demonstrated significantly higher pain-free rates at 2 hours than the control group 6. Lidocaine 4% topical cream resulted in statistically significant improvements in pain intensity scores on both Numeric Analog and Visual Analog Scales 16. Rimegepant was associated with very low rates of high-grade laboratory abnormalities 5.

Safety profiles for several agents were established; Atogepant showed low rates of potentially clinically significant (PCS) laboratory values or ECG findings across multiple trials [3, 11, 15], while standard of care migraine preventive medications also showed low rates of clinical lab/ECG abnormalities 12.

Recent results — preliminary, needs further review

  • The ReMMi-D Digital Therapeutic was associated with a reduction in Monthly Migraine Days (MMD) over a 12-week period (-3.35 vs -2.26).

For the clinician treating this condition

  • AMG334, Atogepant, and Erenumab are supported by evidence for reducing monthly migraine days and/or acute medication use.
  • Galcanezumab is associated with significant reductions in monthly headache days and improved quality-of-life scores.
  • Lidocaine 4% topical cream and DFN-11 provide documented efficacy in acute pain reduction, while Rimegepant shows a favorable laboratory safety profile.

AI synthesis of 10 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bayesian network meta-analysis compares CGRP therapies for episodic migraine
Neurology Meta-analysis
Bayesian network meta-analysis compares CGRP therapies for episodic migraine New migraine drugs show big benefits over placebo for monthly attack counts
This Bayesian network meta-analysis synthesized evidence on six CGRP-targeted therapies for episodic migraine. It found that monoclonal anti…
New migraine drugs cut monthly attacks more than placebo, with injectables slightly better than pills for some people.
medRxiv May 25, 2026
Preliminary Italian data show intravenous eptinezumab reduces pain and symptoms in patients with ongoing episodic or chronic migraine attacks
Neurology Cohort
Preliminary Italian data show intravenous eptinezumab reduces pain and symptoms in patients with ongoing episodic or chronic migraine attacks The Big Discovery:** A preventive migraine drug can start easing pain and light sensitivity during an ongoing attack—in as little as 10 minutes
This preliminary observational study enrolled 31 patients with episodic or chronic migraine experiencing an ongoing attack in an Italian rea…
For the first time, real-world data shows a migraine prevention treatment can also act with surprising speed to stop an attack that’s alread…
Frontiers Apr 10, 2026
Resting-state fMRI shows reduced brain entropy in episodic and chronic migraine compared to healthy controls
Neurology
Resting-state fMRI shows reduced brain entropy in episodic and chronic migraine compared to healthy controls Brain entropy changes in migraine patients compared to healthy controls
This resting-state fMRI study examined brain entropy in adults with episodic migraine, chronic migraine, and healthy controls.
Migraine patients show lower brain complexity in key networks compared to healthy controls, with the biggest drop seen in chronic cases.
medRxiv Apr 6, 2026

Research across Migraine

Related studies from across the Migraine family.

Non-invasive vagus nerve stimulation reduces monthly headache days in migraine patients
Nephrology Meta-analysis
Non-invasive vagus nerve stimulation reduces monthly headache days in migraine patients Trial Shows Vagus Nerve Stimulation Reduces Migraine Frequency
This meta-analysis of 917 patients with migraine found that non-invasive vagus nerve stimulation (nVNS) significantly reduced monthly headac…
Non-invasive vagus nerve stimulation may reduce the number of monthly headache days and the need for acute medication for people living with…
Frontiers Jul 28, 2026
Transcutaneous Vagus Nerve Stimulation utilizes distinct auricular and cervical pathways for non-invasive treatment applications
Neurology Sys. Review
Transcutaneous Vagus Nerve Stimulation utilizes distinct auricular and cervical pathways for non-invasive treatment applications Two different ways to stimulate the vagus nerve for treatment
This narrative review examines the anatomical access points and methodologies for transcutaneous Vagus Nerve Stimulation (tVNS). It distingu…
New research highlights two distinct paths for non-invasive nerve stimulation to treat conditions like migraine and depression.
Frontiers Jul 16, 2026
30% of pediatric patients with migraine report at least one adverse event during pharmacological prophylaxis
Pediatrics Meta-analysis
30% of pediatric patients with migraine report at least one adverse event during pharmacological prophylaxis Trial Shows Specific Side Effects for Children with Migraine
This meta-analysis of 2742 patients evaluates the safety profile of various pharmacological migraine prophylaxis treatments in children and …
About 30% of children and adolescents taking migraine prevention medication report experiencing at least one side effect during treatment.
Jul 8, 2026
Migraine patients may have an increased risk of neovascular age-related macular degeneration
Neurology Sys. Review
Migraine patients may have an increased risk of neovascular age-related macular degeneration Migraine patients may face higher risk of certain eye conditions
This narrative review examines the association between migraine and various retinal conditions, including retinal migraine and AMD. The auth…
New research highlights a link between migraines and age-related macular degeneration, potentially impacting long-term vision for many suffe…
Frontiers Jul 3, 2026
Endometriosis genetic risk score tied to pain, cardiometabolic conditions in both sexes
Genetics & Precision Medicine Meta-analysis
Endometriosis genetic risk score tied to pain, cardiometabolic conditions in both sexes Genetic Risk for Endometriosis Linked to Chronic Pain Conditions
This meta-analysis links an endometriosis polygenic risk score (PRS) to 20 of 29 comorbidities in women and to pain and cardiometabolic cond…
A large genetic study reveals that the same genetic markers linked to endometriosis are also associated with fibromyalgia, migraine, and bac…
medRxiv Jun 24, 2026
Neurotological evaluation distinguishes vestibular migraine from viral neuritis in acute unilateral vestibulopathy
ENT (Otolaryngology) Sys. Review
Neurotological evaluation distinguishes vestibular migraine from viral neuritis in acute unilateral vestibulopathy A single case report shows rapid recovery in vestibular migraine
This case report describes a 40-year-old woman with a history of migraine with aura presenting to the emergency department with vestibular m…
A 40-year-old woman with vestibular migraine recovered her balance quickly. This case suggests that specific reflex patterns help doctors te…
Frontiers Jun 4, 2026
Post-marketing data on CGRP inhibitors show paucity of data and additional risks from chronic biologic use
Drug Pipeline Sys. Review
Post-marketing data on CGRP inhibitors show paucity of data and additional risks from chronic biologic use Post-marketing review highlights safety gaps for migraine CGRP drugs
This narrative review examines monoclonal antibodies and Calcitonin Gene-Related Peptide (CGRP) inhibitors for migraine in the post-marketin…
A review of migraine treatments notes limited data on long-term risks for CGRP inhibitors, urging caution during active monitoring.
Frontiers May 29, 2026
Asia-Pacific experts reach consensus on migraine management and anti-CGRP mAb use in adolescents
Neurology Guideline
Asia-Pacific experts reach consensus on migraine management and anti-CGRP mAb use in adolescents Asia-Pacific experts find consensus on migraine diagnosis and treatment
This guideline presents a Delphi consensus involving 14 headache specialists from seven Asia-Pacific countries. The group evaluated statemen…
Headache specialists across Asia-Pacific agree on key migraine diagnosis and treatment steps, favoring anti-CGRP drugs for most patients but…
Frontiers May 28, 2026
Narrative review refutes causal link between endometriosis and migraine
Neurology Sys. Review
Narrative review refutes causal link between endometriosis and migraine Endometriosis and Migraine Share Hidden Genetic Roots
This narrative review examines the association between endometriosis and migraine. The authors refute a causal relationship and discuss shar…
New genetic research suggests endometriosis and migraine are parallel conditions driven by shared inflammatory pathways, not just hormones.
Frontiers May 15, 2026
Systematic review and meta-analysis compares Rome III and Rome IV criteria for functional abdominal pain disorder prevalence
Pediatrics Meta-analysis
Systematic review and meta-analysis compares Rome III and Rome IV criteria for functional abdominal pain disorder prevalence New Rome IV rules show fewer people have functional abdominal pain compared to older guidelines
This systematic review and meta-analysis evaluates the prevalence of functional abdominal pain disorder (FAPD) and its subtypes using Rome I…
A big review found that using newer rules makes it look like fewer people have stomach pain problems. This change happens because the new ch…
May 15, 2026
Meta-analysis of Chinese decoctions for migraine shows varied efficacy rankings across three botanical interventions.
Drug Pipeline Meta-analysis
Meta-analysis of Chinese decoctions for migraine shows varied efficacy rankings across three botanical interventions. New analysis ranks best herbal treatments for migraine pain
This Bayesian network meta-analysis synthesizes data from 57 randomized controlled trials involving 6,005 patients with migraine.
A new analysis of dozens of Chinese herbal formulas reveals which ones may ease migraine pain, frequency, and duration better than others, o…
Frontiers May 1, 2026
Individualized probabilistic migraine forecasts delivered via electronic diaries in adults with recurrent headaches
Neurology Cohort
Individualized probabilistic migraine forecasts delivered via electronic diaries in adults with recurrent headaches Migraine Forecasting Just Got Smarter
This prospective cohort study of 230 adults with recurrent migraine or tension-type headache evaluated individualized probabilistic forecast…
This tool could help you prepare for migraines before they strike.
medRxiv Apr 23, 2026

Questions about Episodic Migraine

Does resting-state fMRI show lower brain entropy in episodic migraine than in healthy people?

Yes, resting-state fMRI studies show that people with episodic migraine have lower brain entropy in key brain networks compared to healthy people.

Full answer →
Do gepants help reduce monthly migraines in patients with episodic migraine?

Oral gepants like rimegepant and atogepant reduce monthly migraine days in episodic migraine, with rimegepant showing sustained benefits up to 52 weeks in trials.

Full answer →
Does intravenous eptinezumab help reduce pain during an ongoing episodic migraine attack?

Intravenous eptinezumab can reduce pain and symptoms during an ongoing episodic migraine attack, with improvements seen within the first 10 to 20 minutes of infusion.

Full answer →